Literature DB >> 16818519

B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells.

Rita Nahta1, Linda X H Yuan, Derek J Fiterman, Li Zhang, W Fraser Symmans, Naoto T Ueno, Francisco J Esteva.   

Abstract

The antiapoptotic protein Bcl-2 is overexpressed in a majority of breast cancers, and is associated with a diminished apoptotic response and resistance to various antitumor agents. Bcl-2 inhibition is currently being explored as a possible strategy for sensitizing breast cancer cells to standard chemotherapeutic agents. Antisense Bcl-2 oligonucleotides represent one method for blocking the antiapoptotic effects of Bcl-2. In this study, we show that antisense Bcl-2 efficiently blocks Bcl-2 expression, resulting in the apoptosis of breast cancer cells. Antisense Bcl-2-mediated cytotoxicity was associated with the induction of the B cell translocation gene 1 (BTG1). Importantly, knockdown of BTG1 reduced antisense Bcl-2-mediated cytotoxicity in breast cancer cells. Furthermore, BTG1 expression seems to be negatively regulated by Bcl-2, and exogenous expression of BTG1 induced apoptosis. These results suggest that BTG1 is a Bcl-2-regulated mediator of apoptosis in breast cancer cells, and that its induction contributes to antisense Bcl-2-mediated cytotoxic effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818519     DOI: 10.1158/1535-7163.MCT-06-0133

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  20 in total

1.  Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.

Authors:  Stacy L Moulder; W Fraser Symmans; Daniel J Booser; Timothy L Madden; Cindy Lipsanen; Linda Yuan; Abenaa M Brewster; Massimo Cristofanilli; Kelly K Hunt; Thomas A Buchholz; James Zwiebel; Vicente Valero; Gabriel N Hortobagyi; Francisco J Esteva
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

2.  Identification of BTG1 Status in Solid Cancer for Future Researches Using a System Review and Meta-analysis.

Authors:  Xiu-Qiong Chen; Fan-Qiao Meng; Hua Xiong; Ya-Li Wang; Wen-Hua Tang; Yan-Mei Zou
Journal:  Curr Med Sci       Date:  2020-03-13

Review 3.  Recent advances in the molecular diagnostics of gastric cancer.

Authors:  Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

4.  The expression of BTG1 is downregulated in nasopharyngeal carcinoma and possibly associated with tumour metastasis.

Authors:  G G Sun; Y D Wang; Y J Cheng; W N Hu
Journal:  Mol Biol Rep       Date:  2014-07-02       Impact factor: 2.316

5.  Circulating microRNAs involved in multiple sclerosis.

Authors:  Sue Rutherford Siegel; Jason Mackenzie; George Chaplin; Nina G Jablonski; Lyn Griffiths
Journal:  Mol Biol Rep       Date:  2012-01-10       Impact factor: 2.316

6.  BTG1 underexpression is an independent prognostic marker in esophageal squamous cell carcinoma.

Authors:  G G Sun; Y D Wang; Y J Cheng; W N Hu
Journal:  Tumour Biol       Date:  2014-06-27

7.  The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis.

Authors:  G G Sun; Y F Lu; Y J Cheng; W N Hu
Journal:  Tumour Biol       Date:  2013-11-22

8.  BTG1 expression correlates with the pathogenesis and progression of breast carcinomas.

Authors:  S H Sheng; C M Zhao; G G Sun
Journal:  Tumour Biol       Date:  2013-11-24

9.  MicroRNAs are part of the regulatory network that controls EGF induced apoptosis, including elements of the JAK/STAT pathway, in A431 cells.

Authors:  Ibrahim Alanazi; Peter Hoffmann; David L Adelson
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

10.  Expression of BTG1 in hepatocellular carcinoma and its correlation with cell cycles, cell apoptosis, and cell metastasis.

Authors:  G G Sun; Y F Lu; Y J Cheng; C R Yang; Q Liu; S W Jing; X C Han
Journal:  Tumour Biol       Date:  2014-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.